drugset / Trial / NCT05225285
Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents
Phase 3
Unknown
1120 enrolled
Federal University of Espirito Santo
Butantan Institute · collabCentro de Pesquisas René Rachou · collabSecretaria de Estado da Saúde do Espírito Santo - SESA · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To evaluate the efficacy and safety of vaccinating children and adolescents, aged 3 to 17 years, with a two-dose schedule of the inactivated vaccine (Coronavac) against SARS-Cov-2.
Timeline
- Start
- 2022-01-21
- Primary completion
- 2022-06-21
- Completion
- 2023-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | 0.1 ml | — |
| Comparator | BNT162b2 | Messenger RNA (mRNA) | 0.3 ml | — |
| Subject | CoronaVac | Vaccine | 0.5 ml | — |